

Q3 Turnover up 10.7%, PAT up 20.4%

Regulated market bulk approvals received

Mumbai, January 30, 2003

Sun Pharmaceutical Industries Ltd, the speciality pharmaceutical Company announced third quarter results with PAT increased 20.4% to Rs. 559 mill (Q3-01/02 Rs 464mill) and turnover increased 10.7% to Rs. 2179 mill (Q3-01/02 Rs. 1968 mill). Domestic formulation sale for the quarter was up 18.5% to Rs1425 mill (Q3-01/02 Rs 1203mill). Export formulations increased 77.8% to Rs 110 mill this December. EPS for the quarter was up by 20.6% to Rs 11.9 (last year similar quarter Rs 9.9).

For the nine months ending 31st December 2002, PAT increased 16.2% to Rs. 1572 mill (nine months 01/02 Rs 1353 mill) and turnover increased 11.5% to Rs. 6246 mill (nine months 01/02 Rs 5602mill). Domestic formulation sales was up 15.8% to Rs. 4145 mill (nine months 01/02 Rs. 3582mill). Export formulation sales was up 37.1% to Rs. 277 mill (nine months 01/02 Rs. 202mill). EPS for the year to date is Rs. 33.6 as against Rs. 28.6 last year.

The third quarter results were taken on board at a meeting held in Mumbai today.

The company, ranked 5th by domestic prescription product sales, has been consistently adding to market share from 2.78% in November 2001 to 2.92% in December 2002 (ORG Retail Chemist Audit, November 2001, December 2002).

The company won the most number of awards, 4 in all, among 21 participating companies at the IDMA Quality excellence awards for 2002. In the category of formulation units over Rs. 50-cr turnovers, 3 awards were won. The Ahmednagar bulk plant also won a gold medal in the bulk drug unit category, the only company to receive the gold medal.

During the course of the year, the Ankleshwar and Chennai plants received ISO9002 certification. The USFDA approved Ahmednagar bulk drug plant and the Europe approved Panoli site are already ISO 9002 approved. A Certificate Of Suitability for metformin was received during the course of the year and a DMF is expected during the course of the year.

Among the new products launched so far this year, the interesting ones are the asthma metered dose inhaler Fomtide (formoterol), the Antipsychotic Qutipin (quetiapine), Surfact (surfactant for neonates), Rilutor (for movement disorder or amyotrophic lateral sclerosis), Rivamer (for alzheimers disease).

Analysis of data for December 2002 MAT indicates that one of the Company's speciality products, Susten (progesterone) list among the 20 best performing new products launched in the last year.

Sun Pharma continues to be the top rated Company with psychiatrists (1st), neurologists (1st), gastroenterologists (3rd), cardiologists (3rd) orthopedicians (6th); and consultant physicians (6th). An important rank increase was noted in diabetology (4th, up from 6th last year) derma (13th, up from 17th last year), oncology (10th, up from 11th last year), chest physicians (4th, up from 6th last year) (CMARC July- October 02).

To treat respiratory speciality customers better, a new division was carved out-Radiant. This takes the number of divisions to 11. At the Company's R&D Centre SPARC in Baroda, the progress of projects in NCE in three specific therapy areas; as well as that of platform NDDS technologies is fairly satisfactory. The new 16-acre R&D campus in Baroda with 200,000 sq ft research area is on schedule to commence partial operations by August this year. Construction at the Mahakali R&D centre site is also progressing as planned.

Mr. Dilip Shanghvi, Chairman and Managing Director, "Having brought the international dosage form business on track, taking it forward from here in order to make most of the available opportunities, remains our first priority. The second is delivering on our commitments in research, with products in human trials by 04/05"

Contact: *Mira Desai, Corporate Communications*
Phone No's: *022-8211961/ /8230102/ ext. 243*
E-mail: *corpcomm@sunpharma.com, miradesai@hotmail.com*